Biopharma firm Neurocrine Q2 adjusted EPS beats estimates

Neurocrine Biosciences

30/07/2025 21:11

Corrects product sales figure in table to $682 mln from $624.40 mln, and corrects first bullet in overview to say product sales grew 17%, not revenue

Overview

Neurocrine Q2 2025 product sales grows 17% yr/yr, adjusted EPS beats analyst expectations, per LSEG data

Company narrows 2025 net product sales guidance for INGREZZA to $2.5 - $2.55 bln

Co's strong Q2 performance driven by demand for INGREZZA and CRENESSITY

Outlook

Neurocrine narrows 2025 INGREZZA sales guidance to $2.5-$2.55 bln

Company expects strong demand for CRENESSITY to continue

Company forecasts 2025 GAAP SG&A expenses of $1,135-$1,155 mln

Result Drivers

INGREZZA DEMAND - Strong patient demand and expanded formulary access drove 15% sequential growth in INGREZZA sales

CRENESSITY LAUNCH - Robust demand for CRENESSITY with $53 mln in sales and 664 new patient enrollment forms

PIPELINE ADVANCEMENT - Neurocrine advancing neuropsychiatry pipeline with ongoing programs in major depressive disorder and schizophrenia

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$682 mln
Q2 Adjusted EPS
Beat
$1.65
$0.95 (19 Analysts)
Q2 EPS
$1.06
Q2 Adjusted Net Income
Beat
$166.20 mln
$100.10 mln (16 Analysts)
Q2 Net Income
$107.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Neurocrine Biosciences Inc is $163.00, about 17.7% above its July 29 closing price of $134.19

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nPn4cFjkwa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)